Topic:

M&A

Latest Headlines

Latest Headlines

Allergan discloses a secret admirer looking to make an offer. Could it be... Actavis?

Amid a heated takeover fight with Valeant, Allergan says it's got a mystery suitor. But according to The Wall Street Journal 's sources, it's not all that mysterious.

AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal

Looking to build an oncology powerhouse, AstraZeneca has scooped up the diagnostics player Definiens with a down payment of $150 million while executing another drug development partnership with J&J and Pharmacyclics to add to its growing portfolio of immuno-oncology deals

Covidien sells drug-coated balloon for $30M to appease regulators as it barrels toward Medtronic merger

Another hurdle toward the long-anticipated closure of Covidien's $43 billion merger with Medtronic was crossed today. Covidien announced that it is selling its clinical-stage Stellarex drug-coated angioplasty balloon for peripheral artery disease to Spectranetics for $30 million.

LabCorp is buying Covance for $5.6B to cut in on the CRO boom

Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.

IDEXX follows positive earnings with acquisition of Animana

Shares of IDEXX Laboratories rose nearly 5% to $141.67 last week after reporting third-quarter net income that handily beat analyst estimates and announcing the acquisition of Netherlands-based Animana, which makes software for veterinary practices.

Timely deals boost Charles River's balance sheet

A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.

After strong Q3, no $55B deals in AbbVie's future, CEO says. But a smaller one? Maybe

No Shire? No problem for AbbVie. At least, for now.

Zimmer Biomet will be created amid executive shake-up

The long-anticipated acquisition of Biomet by Zimmer Holdings is almost slated to close. The resulting entity will be known as Zimmer Biomet; it has already unveiled a planned new organizational structure and an executive team that draws heavily on the soon-to-be-incorporated Biomet. The deal to create this musculoskeletal giant is expected to close during the first quarter of 2015.

Deal-hungry Perrigo elbows aside competitors for Omega Pharma

Deal-hungry Perrigo is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company has entered exclusive talks to acquire Belgian OTC maker Omega Pharma, inching past big-name competitors like Sanofi, Actavis and Boehringer Ingelheim.

Rating agencies likely to cut Medtronic's credit rating due to looming merger with Covidien

Moody's Investors Service and Standard & Poor's Ratings Services are expected to downgrade Medtronic's debt due to the company's impending merger with Covidien. Under the new rules imposed by the Treasury Department, Medtronic will have to borrow $16.3 billion to fund the $43 billion transaction, as opposed to the initially planned $2.8 billion.